Ali Behbahani
CIK 1613867 · last filed 2026-07-06
Ali Behbahani is a corporate insider who has filed 142 SEC Form 4 insider transactions across 25 companies since 2014. The most recent filing, for GLUE, was dated Jul 6, 2026. Across all open-market trades the lifetime net is +$216.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.75B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.75B
Companies
25
Total Filings
142
Lifetime Open-Market Net
$216.94M
Filer Profile
Reported Address
2855 SAND HILL ROADMENLO PARK, CA 94025
Related Filers
FOREST BASKETT — 1 joint filings, latest 2024-12-23
Carmen Chang — 1 joint filings, latest 2024-12-23
Anthony A. Florence Jr. — 1 joint filings, latest 2024-12-23
Mohamad Makhzoumi — 1 joint filings, latest 2024-12-23
NEA 16 GP, LLC — 1 joint filings, latest 2024-12-23
NEA Partners 16, L.P. — 1 joint filings, latest 2024-12-23
New Enterprise Associates 16, L.P. — 1 joint filings, latest 2024-12-23
SCOTT D SANDELL — 1 joint filings, latest 2024-12-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GLUE | Director | 0 | $14.07 | $0 | $19.95M | 8 | 2026-07-06 |
| BDTX | Director | 4,551,286 | $1.98 | $9.01M | $20.20M | 29 | 2026-06-29 |
| NKTX | Director | — | $2.91 | — | $0 | 7 | 2026-06-11 |
| KRRO | Director | 1,297,893 | $13.81 | $17.92M | $0 | 5 | 2026-06-11 |
| CRSP | Director | 270 | $51.72 | $14.0K | $0 | 11 | 2026-06-09 |
| Arcellx, Inc. (ACLX) Delisted | Director | 0 | $115.07 | $0 | $0 | 7 | 2026-04-28 |
| SGP | Director | 2,989,408 | $27.52 | $82.27M | $15.00M | 2 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 674,554 | $16.35 | $11.03M | $34.97M | 8 | 2025-10-06 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 14,671,794 | $0.06 | $849.5K | $4.77M | 8 | 2025-08-19 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| MBX | 10%+ Owner | 3,114,486 | $59.02 | $183.82M | $8.00M | 1 | 2024-09-17 |
| CVRX | Director | 316 | $2.88 | $910 | $0 | 6 | 2024-06-07 |
| SVRA | 10%+ Owner | 24,471,264 | $5.30 | $129.70M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 0 | $98.22 | $0 | $6.75M | 2 | 2023-06-15 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 3,573 | $11.17 | $39.9K | $0 | 4 | 2023-01-04 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| MINERVA SURGICAL INC (UTRS) Delisted | Director | 2,914 | $0.00 | $0 | $0 | 2 | 2022-06-14 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 0 | $0.00 | $0 | $21.03M | 9 | 2022-05-26 |
| TRVI | 10%+ Owner | 10,421,428 | $15.90 | $165.70M | $31.80M | 4 | 2022-04-13 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,563,257 | $0.49 | $1.27M | $9.51M | 2 | 2021-12-27 |
| MRKR | 10%+ Owner | 1,071,428 | $1.15 | $1.23M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
| ASND | Director | 12,000,000 | $263.51 | $3.16B | $20.00M | 5 | 2019-07-03 |
| NEVRO CORP (NVRO) Delisted | Director | 5,390 | $5.84 | $31.5K | $0 | 8 | 2018-05-23 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | — | — | — | $0 | 2 | 2017-06-02 |
Recent Filings
142 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | GLUE | Other (J) | −1,000,000 | $0 | EDGAR |
| 2026-06-29 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-22 | BDTX | Grant (A) | +8,961 | $14.9K | EDGAR |
| 2026-06-12 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | KRRO | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | NKTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-09 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2026-04-28 | Arcellx, Inc. (ACLX) Delisted | Mixed | −4,631 | $0 | EDGAR |
| 2026-03-20 | BDTX | Grant (A) | +6,919 | $14.9K | EDGAR |
| 2026-03-12 | KRRO | Grant (A) | +207,100 | $2.30M | EDGAR |
Showing 1–10 of 142
Page 1 of 15
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.